Pharmacotherapy for uveitis: Current management and emerging therapy

Robert J. Barry, Quan Dong Nguyen, Richard Wlee, Philip Imurray, Alastair K. Denniston

Research output: Contribution to journalReview article

48 Scopus citations

Abstract

Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects.

Original languageEnglish (US)
Pages (from-to)1891-1911
Number of pages21
JournalClinical Ophthalmology
Volume8
DOIs
StatePublished - Sep 22 2014

Keywords

  • Clinical trials
  • Immunomodulatory therapeutic agents
  • Immunosuppression
  • Inflammation
  • Uvea

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Pharmacotherapy for uveitis: Current management and emerging therapy'. Together they form a unique fingerprint.

  • Cite this

    Barry, R. J., Nguyen, Q. D., Wlee, R., Imurray, P., & Denniston, A. K. (2014). Pharmacotherapy for uveitis: Current management and emerging therapy. Clinical Ophthalmology, 8, 1891-1911. https://doi.org/10.2147/OPTH.S47778